MorphoSys +3% pre-market on the back of the company's R&D agreement with Schering-Plough (SGP), traders say. Under the terms of the two-year deal, MorphoSys will receive an upfront payment, annual user fees and optional R&D funding.

Newratings (http://www.newratings.com/analyst_news/article_1277237.html)